去纤苷的功效与作用

Defibrotide (defiteli) is the first drug approved by the U.S. FDA for the treatment of severe hepatic veno-occlusive disease. It is used for adult or pediatric patients with hepatic venous obstruction (VOD) and abnormal renal or lung function after receiving blood or bone marrow hematopoietic stem cell transplantation (HSCT). The drug has also received "orphan drug" designation.

The functions and functions of defibrotide (defiteli, defiteli) are as follows:

Defiteli (defiteli) is a mixture of single-stranded deoxyoligonucleotide sodium salts produced by controlled depolymerization of porcine intestinal mucosal genomic DNA. Its mechanism of action is complex and has not yet been fully elucidated. The effectiveness of defibrotide (defiteli) was evaluated through 3 research trials conducted on 528 patients. The subjects participating in the 3 trials were all patients diagnosed with VOD symptoms after HSCT and accompanied by abnormal liver or renal function. The overall survival rate 100 days after HSCT was used as the evaluation Indicators and results showed that the survival rate after 100 days for patients treated with defibrotide (defiteli) was 38% to 45%; while data analysis found that HSCT patients who were expected to receive only supportive care or other drug intervention had a survival rate of only 21% to 31% after 100 days.

Defibrotide (defiteli) also has a certain therapeutic effect on multiple myeloma. It has achieved good results in the treatment of multiple myeloma and hepatic veno-occlusive disease caused by chemotherapy and stem cell transplantation, meeting the treatment needs of this rare and fatal disease.

Defibrotide (defiteli) is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide can act on these receptors to produce a variety of downstream effects. In recent years, multiple clinical research results have shown that defibrotide (defiteli) is a safe and effective drug for preventing and treating VOD.